Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.

In the first of a three-part series on the evolution of mRNA manufacturing, this article looks back to before the pandemic, when dogged mRNA researchers and entrepreneurs labored in obscurity pursuing the dream of revolutionizing health care by commandeering the body’s own protein building process to generate quicker, cheaper vaccines and therapeutics. Then the mRNA COVID-19 vaccines stunned the world.

Changed world, new priorities and ways of working? Senior medtech CEOs put their finger on how altered attitudes and new expectations from staff, especially the younger entrants into corporate life, are influencing management styles, now and in the future.

ResMed’s planned buy-out of Germany health care software company Medifox is expected to strengthen its position with out-of-hospital providers outside of the US and strengthen its position as a worldwide leader in health care software solutions.